Prescribing statins to reduce cardiovascular disease: 10 common misconceptions.

Am J Med. 132: 897-899Collins R Reith C Emberson J Armitage J Baigent C Blackwell L et al.

Interpretation of the evidence for the efficacy and safety of statin therapy.

Lancet. 388: 2532-2561

Hyperlidaemia: Diagnosis & Management.

3rd ed. CRC Press, Runz H Rietdorf J Tomic I de Bernard M Beyreuther K Pepperkok R et al.

Inhibition of intracellular cholesterol transport alters presenilin localization and amyloid precursor protein processing in neuronal cells.

J Neurosci. 22: 1679-1689Al-kuraishy HM Al-Gareeb AI Hussein NR Al-naimi MS Rasheed HA

Statins an oft-prescribed drug is implicated in peripheral neuropathy: the time to know more.

J Pak Med Assoc. 69: s108-s112

Oxidized LDL causes endothelial apoptosis by inhibiting mitochondrial fusion and mitochondria autophagy.

Front Cell Dev Biol. 8Vincent A Hinder L Pop-Busui R Feldman E.

Hyperlipidemia: a new therapeutic target for diabetic neuropathy.

J Peripher Nerv Syst. 14: 257-267Isomaa B Henricsson M Almgren P Tuomi T Taskinsen M-R Groop L.

The metabolic syndrome influences the risk of chronic complications in patients with type 2 diabetes.

Diabetologia. 44: 1148-1154

Vascular impairment of epineurial arterioles of the sciatic nerve: implications for diabetic peripheral neuropathy.

Rev Diabet Stud. 12: 13-28Malik RA Newrick PG Sharma AK Jennings A Ah-See AK Mayhew TM et al.

Microangiopathy in human diabetic neuropathy: relationship between capillary abnormalities and the severity of neuropathy.

Diabetologia. 32: 92-102Iqbal Z Bashir B Ferdousi M Kalteniece A Alam U Malik R et al.

Lipids and peripheral neuropathy.

Curr Opin Lipidol. 32: 249-257Chong PH Boskovich A Stevkovic N Bartt RE.

Statin-associated peripheral neuropathy: review of the literature.

Pharmacotherapy. 24: 1194-1203

Statins: mechanism of action and effects.

J Cell Mol Med. 5: 378-387Ward NC Watts GF Eckel RH.

Statin toxicity: mechanistic insights and clinical implications.

Circ Res. 124: 328-350Sehayek E Butbul E Avner R Levkovitz H Eisenberg S.

Enhanced cellular metabolism of very low density lipoprotein by simvastatin. A novel mechanism of action of HMG-CoA reductase inhibitors.

Eur J Clin Invest. 24: 173-178Soran H France M Adam S Iqbal Z Ho JH Durrington PN.

Quantitative evaluation of statin effectiveness versus intolerance and strategies for management of intolerance.

Atherosclerosis. 306: 33-40Soran H Adam S Durrington PN.

Optimising treatment of hyperlipidaemia: quantitative evaluation of UK, USA and European guidelines taking account of both LDL cholesterol levels and cardiovascular disease risk.

Atherosclerosis. 278: 135-142Soran H Adam S Durrington PN

Are recent statin recommendations to employ fixed doses and abandon targets effective for treatment of hypercholesterolaemia? Investigation based on number needed to treat.

Eur J Prevent Cardiol. 24: 76-83Soran H Kwok S Adam S Ho JH Durrington PN

Evidence for more intensive cholesterol lowering.

Curr Opin Lipidol. 28: 291-299

The discovery and development of HMG-CoA reductase inhibitors.

J Lipid Res. 33: 1569-1582Baigent C Blackwell L Emberson J Holland LE Reith C et al.Cholesterol Treatment Trialists’ (CTT) Collaborators

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,00 participants in 26 randomised trials.

Lancet. 376: 1670-1681Soran H Schofield JD Dunnington PN.

Cholesterol, not just cardiovascular risk, is important in deciding who should receive statin treatment.

Eur Heart J. 36: 2975-2983Bhatnagar D Soran H Durrington PN.

Hypercholesterolaemia and its management.

BMJ. 337: a993Soran H Liu Y Adam S Siahmansur T Ho JH Schofield JD et al.

A comparison of the effects of low- and high- dose atorvastatin on lipoprotein metabolism and inflammatory cytokines in type 2 diabetes: results from the Protection Against Nephropathy in Diabetes with Atorvastatin (PANDA) randomized trial.

J Clin Lipidol. 12: 44-55Kearney PM Blackwell L Collins R Keech A Simes J et al.Cholesterol Treatment Trialists’ (CTT) Collaborators

Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis.

Lancet. 371: 117-125Colhoun H Betteridge DJ Durrington P Hitman G Neil HA Livingstone S et al.

Primary Prevention of Cardiovascular Disease with Atorvastatin in Type 2 Diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial.

Lancet. 364: 685-696McFarland A Anoopkumar-Dukie S Arora D Grant G McDermott C Perkins A et al.

Molecular mechanisms underlying the effects of statins in the central nervous system.

Int J Molecul Sci. 15: 20607-20637Mach F Ray K Wiklund O Corsini A Catapano A Bruckert E et al.

Adverse effects of statin therapy: perception vs. the evidence—focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract.

Eur Heart J. 39: 2526-2539Davies J Delfino S Feinberg C Johnson M Nappi V Olinger J et al.

Current and emerging uses of statins in clinical therapeutics: a review.

Lipid Insights. 9: 13-29

The nocebo effect in the context of statin intolerance.

J Clin Lipidol. 10: 739-747Stroes ES Thompson PD Corsini A Vladutiu GD Raal FJ Ray KK et al.

Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society consensus panel statement on assessment, aetiology and management.

Eur Heart J. 36: 1012-1022

Safety and efficacy of stating therapy.

Nature Rev Cardiol. 15: 757-769Gupta A Thompson D Whitehouse A Collier T Dahlof B Poulter N et al.

Adverse events associate with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase.

Lancet. 389: 2473-2481Cohen JD Brinton EA Ito MK Jacobson TA.

Understanding Statin Use in America and Gaps in Patient Education (USAGE): an internet-based survery of 10,138 current and former statin users.

J Clin Lipidol. 6: 208-215Hovingh GK Gandra SR McKendrick J Dent R Wieffer H Catapano AL et al.

Identification and management of patients with statin-associated symptoms in clinical practice: a clinician survey.

Atherosclerosis. 245: 111-117Kon RH Russo MW Ory B Mendys P Simpson Jr, RJ

Misperception among physicians and patients regarding the risks and benefits of statin treatment: the potential role of direct-to-consumer advertising.

J Clin Lipidol. 2: 51-57Preiss D Seshasai S Welsh P Murphy S Ho J Waters D et al.

Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis.

JAMA. 305: 2556-2564Sattar N Preiss D Murray H Welsh P Buckley B de Craen A et al.

Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials.

Lancet. 375: 735-742Sampson UK Linton MF Fazio S.

Are statins diabetogenic?.

Curr Opin Cardiol. 26: 342-347Maki KC Ridker PM Brown WV Grundy SM Sattar N

The Diabetes Subpanel of the National Lipid Association Expert Panel. An assessment by the Statin Diabetes Safety Taskforce: 2014 update.

J Clin Lipidol. 8: S17-S29Swerdlow DI Preiss D Kuchenbaecker KB Holmes MV Engmann JEL Shah T et al.

HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials.

Lancet. 385: 351-361Pinal-Fernandez I Casal-Dominguez M Mammen AL.

Statins: pros and cons.

Medicina Clinica. 150: 398-402Soran H Ho JH Durrington PN.

Acquired low cholesterol: diagnosis and relevance to safety of low LDL therapeutic targets.

Curr Opin Lipidol. 29: 318-326Azmi S Ferdousi M Petropoulos IN Ponirakis G Alam U Fadavi H et al.

Corneal confocal microscopy identifies small-fiber neuropathy in subjects with impaired glucose tolerance who develop type 2 diabetes.

Diabetes Care. 38: 1502-1508Singleton JR Smith AG Russell JW Feldman EL.

Microvascular complications of impaired glucose tolerance.

Diabetes. 52: 2867-2873Asghar O Petropoulos IN Alam U Jones W Jeziorska M Marshall A et al.

Corneal confocal microscopy detects neuropathy in subjects with impaired glucose tolerance.

Diabetes Care. 37: 2643-2646

Association of HMG-CoA reductase inhibitors with neuropathy.

Ann Pharmacother. 37: 274-278Phan T McLeod JG Pollard JD Peiris O Rohan A Halpern J-P.

Peripheral neuropathy associated with simvastatin.

J Neurol Neurosurg Psychiatry. 58: 625-628Gaist D Rodriquez LAG Huerta C Hallas J Sindrup SH.

Are users of lipid-lowering drugs at increased risk of peripheral neuropathy?.

Eur J Clin Pharmacol. 56: 931-933Svendsen TdK Hansen PN Rodriguez LAG Andersen L Hallas J Sindrup SH et al.

Statins and polyneuropathy revisited: case-control study in Denmark, 1999-2013.

Br J Clin Pharmacol. 83: 2087-2095Svendsen TdK Kroigard T Wirenfeldt M Schroder HD Bak S Moller S et al.

Statin use and peripheral nerve function—a prospective follow-up study.

Basic Clin Pharmacol Toxicol. 126: 203-211Warendorf JK Vrancken AFJE van Ejik RPA Visser NA van den Berg LH Notermans NC.

Statins do not increase risk of polyneuropathy.

Neurology. 92: e2136-e2e44Hernández-Ojeda J Roman-Pintos LM Rodriguez-Carrizalez AD Troyo-Sanroman R Cardona-Munoz EG Alatorre-Carranza MdP et al.

Effect of rosuvastatin on diabetic polyneuropathy: a randomized, double-blind, placebo-controlled Phase IIa study.

Diabetes Metab Syndr Obes. 7: 401-407Davis TME Yeap BB Davis WA Bruce DG.

Lipid-Lowering therapy and peripheral sensory neuropathy in type 2 diabetes: the Fremantle Diabetes Study.

Diabetologia. 51: 562-566Pergolizzi Jr, JV Manusson P LeQuang JA Razmi R Zampogna G Taylor Jr, R

Statins and neuropathic pain: a narrative review.

Pain Therapy. 9: 97-111Kazamel M Stino AM Smith AG.

Metabolic syndrome and peripheral neuropathy.

Muscle Nerve. 63: 285-293

Small fiber neuropathy associated with hyperlidemia: utility of cutaneous silent periods and autonomic tests.

Int Sch Res Notices. 579242Obrosova IG Ilnytska O Lyzoguboc VV Pavlov IA Mashtalir N Nadler JL et al.

High-fat diet induced neuropathy of pre-diabetes and obesity: effects of 'healthy' diet and aldose reductase inhibition.

Diabetes. 56: 2598-2608Vincent AM Callaghan BC Smith AL Feldman EL.

Diabetic neuropathy: cellular mechanisms as therapeutic targets.

Nature Rev Neurol. 7: 573-583Tesfaye S Chaturvedi N Eaton S Ward J Manes C Ionescu-Tirgoviste C et al.

Vascular risk factors and diabetic neuropathy.

N Engl J Med. 352: 341-350Mizokami-Stout KR Li Z Foster NC Shah V Aleppo G McGill JB et al.

The contemporary prevalence of diabetic neuropathy in type 1 diabetes: findings from the T1D Exchange.

Diabetes Care. 43: 806-812

Obesity and hyperlipidemia are risk factors for early diabetic neuropathy.

J Diabetes Complications. 27: 436-442Andersen ST Witte DR Fleischer J Andersen H Lauritzen T Jørgensen ME et al.

Risk Factors for the Presence and Progression of Cardiovascular Autonomic Neuropathy in Type 2 Diabetes: ADDITION-Denmark.

Diabetes Care. 41: 2586-2594Jang E-H Park Y-M Hur J Kim M-K Ko S-H Baek K-H et al.

Higher levels of small dense low-density lipoprotein (LDL) are associated with cardiac autonomic neuropathy in patients with type 2 diabetes.

Diabetic Med. 30: 694-701Beyca HH Mesci B Telci Caklili O Mutlu HH Oguz A

Neuropathy associated with hypertriglyceridemia in patients with metabolic syndrome.

Acta Endocrinologica. 12: 26-29Christensen DH Knudsen SørT Gylfadottir SS Christensen LB Nielsen JS Beck-Nielsen H et al.

Metabolic factors, lifestyle habits, and possible polyneuropathy in early type 2 diabetes: a nationwide study of 5,248 patients in the Danish Centre for Strategic Research in Type 2 Diabetes (DD2) Cohort.

Diabetes Care. 43: 1266-1275Fadavi H Tavakoli M Foden P Ferdousi M Petropoulos IN Jeziorska M et al.

Explanations for less small fibre neuropathy in South Asian versus European subjects with type 2 diabetes in the UK.

Diabetes Metab Res Rev. 34: e3044Azmi S Ferdousi M Liu Y Adam S Siahmansur T Ponirakis G et al.

The role of abnormalities of lipoproteins and HDL functionality in small fibre dysfunction in people with severe obesity.

Scientific Rep. : 11

A systematic review and meta-analysis of the serum lipid profile in prediction of diabetic neuropathy.

Sci Rep. 11: 499Andersen ST Grosen K Tankisi H Charles M Andersen NT Andersen H et al.

Corneal confocal microscopy as a tool for detecting diabetic polyneuropathy in a cohort with screen-detected type 2 diabetes: ADDITION-Denmark.

J Diabetes Complications. 32: 1153-1159Adam S Azmi S Ho JH Liu Y Ferdousi M Siahmansur T et al.

Improvements in diabetic neuropathy and nephropathy after bariatric surgery: a prospective cohort study.

Obes Surg. 31: 554-563Azmi S Ferdousi M Liu Y Adam S Iqbal Z Dhage S et al.

Bariatric surgery leads to an improvement in small nerve fibre damage in subjects with obesity.

Int J Obes (Lond). 45: 631-638Perkins BA Dholasania A Buchanan RA Bril V.

Short-term metabolic change is associated with improvement in measures of diabetic neuropathy: a 1-year placebo cohort analysis.

Diabetic Med. 27: 1271-1279Kassem HS Azar ST Zantout MS Sawaya RA.

Hypertriglyceridemia and peripheral neuropathy in neurologically asymptomatic patients.

Neuro Endocrinol Lett. 26: 775-779Al-Shareefi SJ El-Yassin HD Dawoud A-RH

The role of hyperlidemia on nerve conduction.

J Fac Med Baghdad. 50: 105-109Newman CB Preiss D Tobert JA Jacobson TA Page 2nd, RL Goldstein LB et al.

Statin safety and associated adverse events: a scientific statement from the American Heart Association.

Arterioscler Thromb Vasc Biol. 39: e38-e81Otruba P Kanovsky P Hlustik P.

Treatment with statins and peripheral neuropathy: results of 36-months a prospective clinical and neurophysiological follow-up.

Neuroendocrinol Lett. 32: 101-103Hammad MA Sulaiman SAS Alghamdi S Mangi AA Aziz NA Noor DAM.

Statins-related peripheral neuropathy among diabetic patients.

Diabetes Metab Syndr Clin Res Rev. 14: 341-346Corrao G Zambon A Bertu L Botteri E Leoni O Contiero P.

lipid lowering drugs prescription and the risk of peripheral neuropathy: an exploratory case-control study using automated databases.

J Epidemiol Community Health. 58: 1047-1051Tierney EF Thurman DJ Beckles GL Cadwell BL.

Association of statin use with peripheral neuropathy in the US population 40 years of age or older.

J Diabetes. 5: 207-215Nielsen SF Nordestgaard BG.

Statin use before diabetes diagnosis and risk of microvascular disease: a nationwide nested matched study.

Lancet Diabetes Endocrinol. 2: 894-900Macedo AF Taylor FC Casas JP Adler A Prieto-Merino D Ebrahim S.

Unintended effects of statins from observational studies in the general population: systematic review and meta-analysis.

BMC Med. : 12Kristensen FP Christensen DH Callaghan BC Kahlert J Knudsen SrT Sindrup SørH et al.

Statin therapy and risk of polyneuropathy in type 2 diabetes: a Danish cohort study.

Diabetes Care. 43: 2945-2952Tuccori M Montagnani S Mantarro S Capogrosso-Sansone A Ruggiero E Saporiti A et al.

Neuropsychiatric adverse events associated with statins: epidemiology, pathophysiology, prevention and management.

CNS Drugs. 28: 249-272Hyyppä MT Kronholm E Virtanen A Leino A Jula A

Does simvastatin affect mood and steroid hormone levels in hypercholesterolemic men? A randomized double-blind trial.

Psychoneuroendocrinology. 28: 181-194Stewart R Sharples K North F Menkes DB Baker J Simes J.

Long-term association of psychological well-being in a randomized placebo-controlled trial of cholesterol reduction with pravastatin.

Arch Intern Med. 160: 3144-3152Emad M Arjmand H Farpour HR Kardeh B.

Lipid-lowering drugs (statins) and peripheral neuropathy.

Electronic Physician. 10: 6527-6533

Statin adverse effects: a review of the literature and evidence for a mitochondrial mechanism.

Am J Cardiovasc Drugs. 8: 373-418Wang Q Yan J Chen X Li J Yang Y Weng J et al.

Statins: multiple neuroprotective mechanisms in neurodegenerative diseases.

Experimental Neurol. 230: 27-34Berger C Xia F Maurer MH Schwab S.

Neuroprotection by pravastatin in acute ischemic stroke in rats.

Brain Res Rev. 58: 48-56Torrandell-Haro G Branigan GL Vitali F Geifman N Zissimopoulos JM

Brinton RD. Statin therapy and risk of Alzheimer's and age-related neurodegenerative diseases.

Trans Res Clin Intervent. 6: e12108Wong WB Lin VW Boudreau D Devine EB.

Statins in the prevention of dementia and Alzheimer's disease: a meta-analysis of observational studies and an assessment of confounding.

Pharmacoepidemiol Drug Saf. 22: 345-358Posvar EL Radulovic LL Cilla Jr, DD Whitfield LR Sedman AJ

Tolerance and pharmacokinetics of single-dose atorvastatin, a potent inhibitor of HMG-CoA reductase, in healthy subjects.

J Clin Pharmacol. 36: 728-731Schultz BG Patten DK Berlau DJ.

The role of statins in both cognitive impairment and protection against dementia: a tale of two mechanisms.

Transl Neurodegener. 7: 1-11Wagstaff LR Mitton MW Arvik B Doraiswamy P.

Statin-associated memory loss: analysis of 60 case reports and review of the literature.

Pharmacotherapy. 23: 871-880

Statins: then and now.

Methodist DeBakey Cardiovasc J. 15: 23-31Cholesterol Treatment Trialists’ (CTT) Collaborators

The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials.

Lancet. 380: 581-590Perez-Matos MC Morales-Alvarez MC Mendivil CO

Lipids: a suitable therapeutic target in diabetic neuropathy?.

J Diabetes Res. 2017: 1-9Cho YR Lim JH Kim MY Kim TW Hong BY Kim Y-S et al.

Therapeutic effects of fenofibrate on diabetic peripheral neuropathy by improving endothelial and neural survival in db/db mice.

PLoS ONE. 9: 1-12Ferdousi M Kalteniece A Azmi S Petropoulos IN Ponirakis G Alam U et al.

Diagnosis of neuropathy and risk factors for corneal nerve loss in type 1 and type 2 diabetes: a corneal confocal microscopy study.

Diabetes Care. 44: 150-156Wiggin TD Sullivan KA Pop-Busui R Amato A Sima AAF Feldman EL.

Elevated triglycerides correlate with progression of diabetic neuropathy.

Diabetes. 58 ()Corcia P De Toffol B Hommet C Autret A

Jonville-Bera A. Severe toxic neuropathy due to fibrates.

J Neurol Neurosurg Psychiatry. 66: 410Bergeron N Phan BAP Ding Y Fong A Krauss RM.

Proprotein convertase subtilisin/kexin type 9 inhibition: a new therapeutic mechanism for reducing cardiovascular disease risk.

Circulation. 132: 1648-1666Abifadel M Varret M Rabès J-P Allard D Ouguerram K Devillers M et al.

Mutations in PCSK9 cause autosomal dominant hypercholesterolemia.

Nat Genet. 34: 154-156Ridker PM Revkin J Amarenco P Brunell R Curto M Civeira F et al.

Cardiovascular efficacy and safety of bococizumab in high-risk patients.

N Engl J Med. 376: 1527-1539Sabatine MS Giugliano RP Keech AC Honarpour N Wiviott SD Murphy SA et al.

Evolocumab and clinical outcomes in patients with cardiovascular disease.

N Engl J Med. 376: 1713-1722Schwartz GG Steg G Szarek M Bhatt DL.

Alirocumab and cardiovascular outcomes after acute coronary syndrome.

N Engl J Med. 379: 2097-2107Squizzato A Suter MB Nerone M Giugliano RP Dentali F Maresca AM et al.

PCSK9 inhibitors for treating dyslipidemia in patients at different cardiovascular risk: a systematic review and meta-analysis.

Intern Emerg Med. 12: 1043-1053Levenson AE Shah AS Khoury PR Kimball TR Urbina EM de Ferranti SD et al.

Obesity and type 2 diabetes are associated with elevated PCSK9 levels in young women.

Pediatr Diabetes. 18: 755-760Levenson AE Wadwa RP Shah AS Khoury PR Kimball TR Urbina EM et al.

PCSK9 is increased in youth with type 1 diabetes.

Diabetes Care. 40: e85-ee7Levenson AE Milliren CE Biddinger SB Ebbeling CB Feldman HA